Pacific Edge Appoints Chief Operating Officer

28 July 2022
Pacific Edge Appoints Chief Operating Officer
Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) is today pleased to announce the
appointment of Darrell Morgan as Chief Operating Officer.
Darrell has extensive experience in senior leadership and executive roles in large, mid-sized and
virtual pharmaceutical companies in the UK, Europe and New Zealand. He has more than 37
years’ experience in pharmaceutical R&D, immunodiagnostics and device development for drug
delivery across human and animal health, in R&D, technical operations and customer-facing
roles.
As Chief Operating Officer, Darrell will be a key leader in the Dunedin office, and responsible for
Pacific Edge’s global laboratory operations, manufacturing, logistics, inventory management, the
quality and regulatory compliance functions and operationalizing people and culture initiatives.
He will have a focus on project management, people and culture, and operational excellence to
optimize effectiveness, efficiency and on time delivery of products and services.
Darrell will join Pacific Edge on 3 October 2022 and report to Chief Executive Dr Peter Meintjes
as a member of the C-Suite team. He will be based in Dunedin.
Since 2013, Darrell has been a senior leader with animal health company Argenta Research
where his roles have included Global Head of Pharmaceutical Sciences, VP Customer
Relationships – Pharmaceutical Sciences, and Product Development Director – Technical
Operations. Prior to Argenta Research, he worked for global biopharmaceutical company UCB in
the UK for eight years in senior roles with a focus on sterile drug product and medical device
development.
Pacific Edge Chief Executive Dr Peter Meintjes, said: “We are delighted to welcome Darrell to
Pacific Edge. His experience in global organizations of varied sizes in a range of roles focused
on product and service delivery will be of great value to Pacific Edge and its partners and
customers as we continue to drive increased adoption of our suite of Cxbladder diagnostics.”
Darrell said: “I have been impressed by the strong momentum I have seen from Pacific Edge as
it expands globally, with a focus on the US. I look forward to working with the team to ensure
quality and scale continues as the company grows.”
Darrell is a chartered biologist, with post graduate diplomas in industrial pharmaceutical sciences
and management, people and change.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:
Dr Peter Meintjes Richard Inder
Chief Executive The Project
Pacific Edge P: +64 21 645 643
P: +64 22 032 1263

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX/ ASX: PEB) is a global cancer diagnostics company leading the way in the development and
commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or
surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of
Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

About Cxbladder www.cxbladder.com
Cxbladder is a non-invasive genomic urine test optimized for the detection and management of bladder cancer. The
Cxbladder evidence portfolio developed over the past 14 years includes more than 20 peer reviewed publications
for primary detection, surveillance, adjudication of atypical urine cytology and equivocal cystoscopy. Cxbladder is
the focal point of numerous ongoing and planned clinical studies to generate an ever-increasing body of clinical
utility evidence supporting adoption and use in the clinic to improve patient health outcomes. Cxbladder is
reimbursed by CMS and has been trusted by over 2,000 US urologists in the diagnosis and management of more
than 80,000 patients, including the option for in-home sample collection. In New Zealand, Cxbladder is accessible to
70% of the population via public healthcare and all residents have the option of buying the test online.